Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABIOS: Cabozantinib, Abiraterone, and Nivolumab in mHSPC
NCT04477512Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabozantinib and nivolumab in prostate cancer (PCa) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Frequency of dose-limiting toxicities at Cycle 1. Started Feb 2021; status: completed.
02
Drugs
cabozantinibnivolumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04477512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477512.